See the DrugPatentWatch profile for vascepa

Based on the information available, I was unable to find a specific date or timeline for when insurance will cover generic Vascepa. However, I can provide some context and insights that may help answer your question.

Vascepa (icosapent ethyl) is a prescription medication approved by the FDA to lower triglyceride levels in adult patients. It is manufactured by Amarin Pharma, Inc. Vascepa has been available on the market since 2013 [1].

In December 2019, the U.S. Food and Drug Administration (FDA) approved four generic versions of Vascepa [2]. The approval of generic Vascepa may lead to increased competition and potentially lower prices, making it more accessible and affordable for patients. However, it is important to note that insurance coverage for generic Vascepa will depend on various factors, including the specific insurance plan, formulary, and any applicable coverage rules or restrictions.

According to DrugPatentWatch.com, Amarin's Vascepa patent expired in December 2020 [3]. With the expiration of the patent, it is expected that more generic versions of Vascepa will become available, which could lead to increased competition and further price reductions. However, insurance coverage for these generics will still depend on individual insurance plans and policies.

In summary, while there is no specific date or timeline for when insurance will cover generic Vascepa, the approval of generic versions and the expiration of Vascepa's patent may contribute to increased accessibility and affordability of the medication. It is recommended to contact your insurance provider for specific information regarding coverage and reimbursement for generic Vascepa.

Sources:

1. "Vascepa (icosapent ethyl) Capsules." U.S. Food and Drug Administration. <https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/vascepa-icosapent-ethyl-capsules>.
2. "FDA Approves First Generic of Vascepa to Reduce Risk of Cardiovascular Events in High-Risk Patients." U.S. Food and Drug Administration. <https://www.fda.gov/news-events/press-announcements/fda-approves-first-generic-vascepa-reduce-risk-cardiovascular-events-high-risk-patients>.
3. "Vascepa (icosapent ethyl) - Amarin Pharma Inc." DrugPatentWatch.com. <https://www.drugpatentwatch.com/drugs/vascepa>.